InsidersTradesSigma
Track the MACROGENICS, INC. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €268.6m. The latest transaction was reported on 17 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Jay Siegel. Every trade is openly available.
Analysts rate MACROGENICS, INC. Buy (bullish), based on 4 analysts. Average price target: US$7.25.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
MACROGENICS, INC. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. It is listed on NASDAQ under the ticker MGNX.